| NASDAQ (usa) |
|
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
| DAX (german) |
|
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Medeon Biodesign Inc. (TWO: 6499)
6499 Technical Analysis
4
| As on 26th Dec 2025 6499 STOCK Price closed @ 99.30 and we RECOMMEND Buy for LONG-TERM with Stoploss of 78.91 & Strong Buy for SHORT-TERM with Stoploss of 40.27 we also expect STOCK to react on Following IMPORTANT LEVELS. |
6499STOCK Price
| Open | 95.70 | Change | Price | % |
| High | 99.30 | 1 Day | 4.50 | 4.75 |
| Low | 95.70 | 1 Week | 7.60 | 8.29 |
| Close | 99.30 | 1 Month | 2.30 | 2.37 |
| Volume | 1193194 | 1 Year | 57.05 | 135.03 |
| 52 Week High 145.00 | 52 Week Low 36.45 | ||||
TWO Taiwan Most Active Stocks
| 1815 | 92.60 | 1.42% |
| 5498 | 46.50 | 9.93% |
| 3260 | 221.50 | -0.89% |
| 1785 | 66.60 | -4.86% |
| 3264 | 102.00 | 9.56% |
| 4979 | 303.00 | 2.89% |
| 5351 | 43.80 | 5.67% |
| 6244 | 22.65 | 0.00% |
| 8074 | 50.50 | 9.90% |
| 8043 | 90.00 | 1.81% |
TWO Taiwan Top Gainers Stocks
TWO Taiwan Top Losers Stocks
| 6499 Daily Charts |
6499 Intraday Charts |
Whats New @ Bazaartrend |
6499 Free Analysis |
|
|
6499 Important Levels Intraday
| RESISTANCE | 106.24 |
| RESISTANCE | 104.01 |
| RESISTANCE | 102.64 |
| RESISTANCE | 101.26 |
| SUPPORT | 97.34 |
| SUPPORT | 95.96 |
| SUPPORT | 94.59 |
| SUPPORT | 92.36 |
6499 Forecast December 2025
| 4th UP Forecast | 112.69 |
| 3rd UP Forecast | 108.4 |
| 2nd UP Forecast | 105.74 |
| 1st UP Forecast | 103.09 |
| 1st DOWN Forecast | 95.51 |
| 2nd DOWN Forecast | 92.86 |
| 3rd DOWN Forecast | 90.2 |
| 4th DOWN Forecast | 85.91 |
6499 Weekly Forecast
| 4th UP Forecast | 113.75 |
| 3rd UP Forecast | 109.12 |
| 2nd UP Forecast | 106.25 |
| 1st UP Forecast | 103.39 |
| 1st DOWN Forecast | 95.21 |
| 2nd DOWN Forecast | 92.35 |
| 3rd DOWN Forecast | 89.48 |
| 4th DOWN Forecast | 84.85 |
6499 Forecast2025
| 4th UP Forecast | 330.06 |
| 3rd UP Forecast | 256.05 |
| 2nd UP Forecast | 210.31 |
| 1st UP Forecast | 164.56 |
| 1st DOWN Forecast | 34.04 |
| 2nd DOWN Forecast | -11.71 |
| 3rd DOWN Forecast | -57.45 |
| 4th DOWN Forecast | -131.46 |
Medeon Biodesign Inc. ( TWO Taiwan Symbol : 6499 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
6499 Other Details
| Segment | EQ | |
| Market Capital | 4679439360.00 | |
| Sector | Healthcare | |
| Industry | Medical Instruments & Supplies | |
| Offical website | > echo $website ; ?> | |
6499 Address
![]() |
||
6499 Latest News
6499 Business Profile
Medeon Biodesign, Inc. develops and markets medical device solutions in Taiwan. It focuses on developing devices for minimally invasive surgeries, such as Duett, a vascular graft system; ClickClean, a solution to view throughout laparoscopic surgeries; AbClose to prevent port site herniation caused by improper closure; Mercury to widen the narrowed prostatic urethra tissue creating an open urethral lumen for normal urinary flow; PUMA, a solution to treat orthopedic extremity injuries; and Cross-Seal, a large-bore closure device. The company was founded in 2012 and is headquartered in Taipei, Taiwan. Address:
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service

